ACR 2018 In-Depth

Etanercept Biosimilar Demonstrates Similar Efficacy to Reference Product in RA

Etanercept Biosimilar Demonstrates Similar Efficacy to Reference Product in RA

By

The efficacy of biosimilar GP2015 was comparable to that of etanercept over 48 weeks.

Rapid 1-Year Remission Linked to Better Structural Damage Outcomes in RA

Rapid 1-Year Remission Linked to Better Structural Damage Outcomes in RA

By

Investigators evaluated radiographic progression and the newly pathological joints in patients with early RA.

Efficacy of Tocilizumab in RA Not Affected by Obesity, Comorbidity Burden

Efficacy of Tocilizumab in RA Not Affected by Obesity, Comorbidity Burden

By

The effectiveness of tocilizumab was comparable in patients with RA regardless of comorbidity burden or obesity.

Increased Opioid Prescribing Linked to Chronic Usage in Patients With RA

Increased Opioid Prescribing Linked to Chronic Usage in Patients With RA

By

A physician's baseline opioid prescribing rate was a strong predictor of a patient's future opioid use.

Strong Association Between Active RA and Cardiovascular Events After Initial Diagnosis

Strong Association Between Active RA and Cardiovascular Events After Initial Diagnosis

By

RA is associated with an increased risk for cardiovascular disease and mortality.

Increased Risk for Chronic Kidney Disease in Rheumatoid Arthritis

Increased Risk for Chronic Kidney Disease in Rheumatoid Arthritis

By

Patients with rheumatoid arthritis may have a significantly higher risk of developing chronic kidney disease.

Influenza Vaccination Low in Rheumatoid Arthritis, Psoriatic Arthritis

Influenza Vaccination Low in Rheumatoid Arthritis, Psoriatic Arthritis

By

Patients with rheumatoid arthritis or psoriatic arthritis have a low influenza vaccination rate, despite the recommendation from the CDC to be vaccinated annually.

Novel JAK Inhibitor Peficitinib Effective, Tolerable in Treating Rheumatoid Arthritis

Novel JAK Inhibitor Peficitinib Effective, Tolerable in Treating Rheumatoid Arthritis

By

Peficitinib significantly reduced symptoms in patients with rheumatoid arthritis and demonstrated tolerability and safety.

JAK Inhibitors, Biologic DMARDs Yield Better Quality of Life Outcomes in Rheumatoid Arthritis

JAK Inhibitors, Biologic DMARDs Yield Better Quality of Life Outcomes in Rheumatoid Arthritis

By

JAK inhibitors and biologic DMARDs demonstrated better SF-36 Physical Component Summary and Mental Component Summary scores at 12 weeks.

Sign Up for Free e-newsletters